recruiting not so easy, page-10

Hello Croc

"why not do it on both types"

If you look at the Biotech Showcase Presentation of 13 Jan 2014 on the BLT website you will see Cohort 1 is two patients dosed sequentially.

If you call Duke Clinical Research you will find that during the safety studies trials are typically made healthy patients because it is more difficult to measure adverse safety effects on sick patients.

So I would expect cohort 1 TO 2 will be carried out on healthy people. I would expect cohorts 4 and 5 to be carried out on HCV suffers with a view to getting a feeling for efficacy.

I would expect the patients in cohorts 2 to 4 will depend on the results to cohort 1 and 2. As a scientist, but not in medicine, this would seem to me to be the logical way of doing things.

This post in observation based on a couple of phone calls. I would appreciate comments from medical professionals who have actually supervised trials like BLT are about to commence. They have the experience and expertise that I do not have.